 |
|
Long-term Obligations to Human Subjects in Clinical Trials
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Issues relating to clinical trials in developing countries have been debated in different forums.1-3 We have identified an additional aspect that relates to the moral duties that researchers should address after the termination of a clinical trial.4 To illustrate this point, we will describe our experience with a clinical trial in which we participated between 1993 and 1998.5 The 181 participants at our site in Mexico City received benefits during the trial that included access to primary care, periodic measurement of CD4 cell counts and viral load counts, referral to secondary clinical care, and psychological support. Because collaboration was established with a nongovernmental organization, community network support also was provided. Procedures were reviewed and approved by the appropriate local and international review boards and all patients provided written informed consent.
Our estimates of the short-term impact of the termination of the clinical trial include the following: 84% . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial
Fred Gordin, Richard E. Chaisson, John P. Matts, Carol Miller, Maria de Lourdes Garcia, Richard Hafner, Jose Luis Valdespino, Jacqueline Coberly, Mauro Schechter, Alan J. Klukowicz, M. Anita Barry, Richard J. O'Brien, and for the Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group
JAMA. 2000;283(11):1445-1450.
ABSTRACT
| FULL TEXT
|
